Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
JAMA Oncology|March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Yue Shi, Matthew Deek, et al.
Cancer Research|November 21, 2025
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancerRajendra Kumar, Sheila Jonnatan, David E Sanin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
Prostate Cancer and Prostatic Diseases|February 10, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R Wise, Russell K Pachynski, Samuel R Denmeade, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
JAMA Oncology|March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Yue Shi, Matthew Deek, et al.
Cancer Research|November 21, 2025
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancerRajendra Kumar, Sheila Jonnatan, David E Sanin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
Prostate Cancer and Prostatic Diseases|February 10, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R Wise, Russell K Pachynski, Samuel R Denmeade, et al.
Pageof 16